Literature DB >> 28791393

Elevated expression of yes‑associated protein is associated with the malignant status and prognosis of laryngeal squamous cell carcinoma.

Chunchen Pan1, Zhihui Du1, Zhaogen Cai2, Yun Liu1, Yanbo Sun1, Jin Chen1, Ting Tong1, Qingguo Chen1, Liangqiang Zhou1, Dan Bing1, Yanling Tao1, Hanqi Chu1.   

Abstract

Previous studies have demonstrated that elevated yes‑associated protein (YAP) expression is associated with tumor aggression and poor prognosis in various types of human cancer. However, the clinicopathological significance and the prognostic value of YAP in laryngeal squamous cell carcinoma (LSCC) is unknown. The aim of the present study was to identify the expression pattern and prognostic significance of YAP in patients with LSCC. YAP mRNA and protein expression levels were examined in fresh and archived LSCC samples using the reverse transcription‑quantitative polymerase chain reaction, immunohistochemistry (IHC) and western blotting. The association between YAP expression levels with the malignant status and prognosis of patients with LSCC was analyzed. Upregulated protein and mRNA expression levels of YAP were detected in LSCC tissues compared with paired healthy surgical margin tissues. Positive expression of YAP was identified in 84/121 (69.4%) LSCC tissues and in 4/30 (13.3%) healthy surgical margin tissues by IHC. Positive YAP protein expression was significantly associated with clinical stage, TNM classification, lymph node metastasis and differentiated degree. Patients with positive YAP expression exhibited a significantly decreased overall survival time compared with patients with negative YAP expression (P=0.0002). Multivariate analysis indicated that the level of YAP expression was an independent prognostic factor for poor survival in patients with LSCC (P=0.012). In conclusion, the expression level of YAP was significantly increased in LSCC and associated with the malignant status of LSCC. Therefore, YAP may represent a novel biomarker for predicting the prognosis of patients with LSCC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28791393     DOI: 10.3892/mmr.2017.7187

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  4 in total

1.  miR-506 is a YAP1-dependent tumor suppressor in laryngeal squamous cell carcinoma.

Authors:  Changhui Gao; Shousen Hu
Journal:  Cancer Biol Ther       Date:  2019-03-25       Impact factor: 4.742

2.  The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.

Authors:  Jacqueline E Mann; Aditi Kulkarni; Andrew C Birkeland; Judy Kafelghazal; Julia Eisenberg; Brittany M Jewell; Megan L Ludwig; Matthew E Spector; Hui Jiang; Thomas E Carey; J Chad Brenner
Journal:  Head Neck       Date:  2019-05-15       Impact factor: 3.821

3.  Knockdown of YAP inhibits growth in Hep-2 laryngeal cancer cells via epithelial-mesenchymal transition and the Wnt/β-catenin pathway.

Authors:  Xiaomin Tang; Yuxuan Sun; Ganglun Wan; Jiaqiang Sun; Jingwu Sun; Chunchen Pan
Journal:  BMC Cancer       Date:  2019-07-03       Impact factor: 4.430

4.  The prognostic value of YAP1 on clinical outcomes in human cancers.

Authors:  Ying Wu; Yanshen Hou; Peng Xu; Yujiao Deng; Kang Liu; Meng Wang; Tian Tian; Cong Dai; Na Li; Qian Hao; Dingli Song; Ling Hui Zhou; Zhijun Dai
Journal:  Aging (Albany NY)       Date:  2019-10-15       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.